Overview

Study Evaluating HKI-272 in Tumors

Status:
Completed
Trial end date:
2007-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose (MTD) for HKI-272. In addition, this study will examine the effects of the study drug on your tumor, and how your body uses and eliminates HKI-272.
Phase:
Phase 1
Details
Lead Sponsor:
Puma Biotechnology, Inc.